{"id":"W2794958179","doi":"10.1053/j.gastro.2018.03.032","title":"Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease","year":2018,"lang":"en","type":"review","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"UCB Pharma; Toray Industries; Kyowa Hakko Kirin; Meso Scale Diagnostics; Ferring Research Institute; Novo Nordisk; Teva Pharmaceutical Industries; Janssen Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Arrien Pharmaceuticals; Celgene; Shire; Heron Therapeutics; Eli Lilly and Company; AstraZeneca; Western University; Takeda Pharmaceutical Company; Roche","keywords":"Medicine; Clinical trial; Crohn's disease; Delphi method; Disease; Inflammatory bowel disease; Clinical endpoint; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002149296,0.0002996762,0.000934823,0.0001302424,0.00003623051,0.000003479451,0.0002575595,0.0001815398,0.000006756215],"category_scores_gemma":[0.00006710083,0.0002704615,0.0007056862,0.00003090203,0.0001966475,0.000002692705,0.00006658148,0.00001478683,0.00000183837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004430555,"about_ca_system_score_gemma":0.000347378,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":6.23839e-7,"about_ca_topic_score_gemma":0.000009524281,"domain_scores_codex":[0.9978702,0.0001035418,0.001201981,0.0004595135,0.00009175653,0.0002730226],"domain_scores_gemma":[0.9978131,0.0000251078,0.001221226,0.0005615026,0.00028354,0.00009549464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03418687,0.005814679,0.005274289,0.2227356,0.009178376,0.00001946487,0.001022534,0.00001383689,0.0323976,0.0001966155,0.004641417,0.6845187],"study_design_scores_gemma":[0.006575201,0.003848597,0.01709736,0.003407934,0.005276781,0.000009664647,0.00005288919,0.00002810509,0.04015642,0.00007622785,0.9227685,0.0007023223],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.3527555,0.6193638,0.01336101,0.00001186066,0.0007742495,0.006363786,0.007346692,0.00001346807,0.000009638778],"genre_scores_gemma":[0.03983194,0.9387778,0.008397406,0.0000246465,0.0004389289,0.003767578,0.008110957,0.0001795962,0.0004711151],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9181271,"threshold_uncertainty_score":0.9999748,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02560819691949784,"score_gpt":0.3108939057775107,"score_spread":0.2852857088580129,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}